DPP4 and dementia: Although major clinical trials suggested a neutral cardiovascular effect of DPP4 inhibitors (27) and the present study did not favor a beneficial effect of vildagliptin on dementia, DPP4 inhibitors can at least be safely used for glycemic control in older patients because of a high tolerability and a lack of hypoglycemic risk (28).